24228-41-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(phenylethyl)-4-(ethoxycarbonyl)piperidine is used as a pharmaceutical agent for its potential therapeutic applications in treating neurological disorders such as attention deficit hyperactivity disorder (ADHD). Its potent and selective dopamine reuptake inhibition properties make it a promising candidate for research and development in this field.
Used in Research and Development:
1-(phenylethyl)-4-(ethoxycarbonyl)piperidine is used as a research compound for studying its pharmacological properties and potential applications in the treatment of neurological disorders. Its structure and mechanism of action provide valuable insights into the development of new drugs and therapies for various conditions.
Used in Recreational Drug Market:
1-(phenylethyl)-4-(ethoxycarbonyl)piperidine is used as a recreational drug due to its stimulant and hallucinogenic effects. However, it is important to note that the use of EPPP for recreational purposes is not recommended due to its potential health risks and legal implications.

Upstream product

• 1126-09-6 4-carbethoxypiperidine 
• 103-63-9 1-phenyl-2-bromoethane 

Downstream Products

• 796847-71-7 1-(2-phenylethyl)-4-piperidine carboxylic acid hydrochloride 
• 383362-49-0 4-[(bis(4-fluorophenyl)methylamino)carbonyl]-1-(phenylethyl)piperidine 
• 383362-71-8 4-[(Bis(4-fluorophenyl)methylamino)methyl]-1-[2-(phenyl)ethyl]piperidine 
• 807315-42-0 1-phenethyl-piperidine-4-carboxylic acid 
• 67686-02-6 1-(2-phenylethyl)-4-(hydroxymethyl)piperidine 

Relevant academic research and scientific papers

COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT

Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.

Structure-activity relationship studies of novel 4-[2-[bis(4- fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: Synthesis and biological evaluation at the dopamine and serotonin transporter sites

Several analogs of the potent dopamine (DA) transporter ligand 4-[2- [bis(4-fluorophenyl)-methoxy]ethyl]-1-(3-phenylpropyl)piperidine, 1b, were made and biologically evaluated for their binding at the DA and serotonin (5HT) transporters in rat striatal membranes. Different alkyl chain lengths and substitutions were introduced in these molecules to generate an optimum activity and selectivity for the DA transporter. In general, unsubstituted and fluoro-substituted compounds were the most active and selective for the DA transporter. The compound 4-[2(diphenylmethoxy)ethyl]-1-benzylpiperidine, 9a, showed high potency and was the most selective for the DA transporter (5HT/DA = 49) in this series of compounds. Some of these novel analogs were found to be more selective in binding at the DA transporter than the original GBR 12909 molecule, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3- phenylpropyl)piperidine.

(N-phthalimidoalkyl) piperidines useful as treatments for psychosis

There is described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.